MBSR Mechanisms in GAD

Status Recruiting

Clinical Trial Summary

The purpose of this study is to understand the neural mechanisms that drive response to MBSR compared to stress education in patients with generalized anxiety disorder (GAD), and to examine the degree to which sex differences in MBSR response are explained by sex differences in these mechanisms. A total of 150 eligible participants with a primary diagnosis of GAD will be randomized to either an 8-week group MBSR or stress education program. The study will include preliminary screening, experimental visits, including fMRI, group intervention visits, and assessments at baseline, endpoint, and 3-month follow-up.

Clinical Trial Description

Mindfulness-Based Stress Reduction (MBSR) has demonstrated efficacy for Generalized Anxiety Disorder (GAD), yet there remains a major knowledge gap about its neural mechanisms. This study will examine functional activation of brain regions associated with the fear extinction network (ventromedial prefrontal cortex (vmPFC), hippocampus, and amygdala) as a specific probe of the 'instinctual' type of emotion regulation as well as large-scale functional connectivity as a marker of neural plasticity changes. Sex differences in MBSR-induced neural changes and their relationship to sex differences in clinical GAD response will be examined. Finally, a novel statistical approach will be used to explore whether baseline neural measures can predict neural changes and clinical symptom reduction to identify likely MBSR responders. The unique combination of a focus on GAD, an anxiety condition with established emotion regulation difficulties implicating target neural circuits, previously demonstrated MBSR efficacy, and sex differences with rigorous fMRI behavioral probes with novel analytic approaches ought to provide major new insights about MBSR versus stress education mechanisms and sex considerations, moving towards precision medicine that could guide future treatment development research. Eligible participants with Generalized Anxiety Disorder will be 2:1 randomized to group intervention with MBSR or stress education classes. They will participate for 13-14 weeks plus one 3 month follow up assessment (23-24 weeks from screening). Full participation includes screening, baseline, endpoint and 3 month follow up assessments, two sets of experimental days 12 weeks apart which include fMRI scans, and 8 weeks of the assigned group intervention (either MBSR or stress education). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05064813
Study type	Interventional
Source	NYU Langone Health
Contact	Leo Almada-Makebish
Phone	1-888-449-6779
Email	anxietystudy@nyulangone.org
Status	Recruiting
Phase	N/A
Start date	November 1, 2021
Completion date	June 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03420456` - Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study	N/A
Active, not recruiting	`NCT05530642` - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel	N/A
Withdrawn	`NCT02382224` - Worry Exposure for Generalized Anxiety Disorder	N/A
Completed	`NCT02256566` - Cognitive Training for Mood and Anxiety Disorders	N/A
Completed	`NCT02306356` - Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting	N/A
Completed	`NCT01958788` - Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder	N/A
Completed	`NCT01681329` - Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder	N/A
Completed	`NCT01201967` - A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients	Phase 4
Completed	`NCT01342120` - PHARMO Institute Seroquel Safety Study	N/A
Completed	`NCT01337713` - Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)	N/A
Completed	`NCT01971203` - Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat	N/A
Completed	`NCT00961298` - An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder	Phase 4
Completed	`NCT01203293` - Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector	Phase 1
Terminated	`NCT01244711` - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines	Phase 4
Completed	`NCT00711737` - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months	N/A
Completed	`NCT00744627` - Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.	Phase 3
Completed	`NCT00515242` - Therapeutic Massage for Generalized Anxiety Disorder	Phase 1/Phase 2
Completed	`NCT00537615` - An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers	Phase 1
Completed	`NCT00525226` - Evaluating the Effects of Stress in Pregnancy	N/A
Completed	`NCT00620776` - Combined Treatment for Generalized Anxiety Disorder (GAD)	Phase 2